A recent study has unveiled the potential for semaglutide, a medication commonly prescribed for obesity and diabetes, to be manufactured at an astonishingly low cost of merely $3 per month. This groundbreaking development could significantly enhance accessibility to essential treatments in over 160 nations, particularly benefiting populations grappling with rising obesity rates and diabetes, especially in low- and middle-income countries.
A Shift Towards Accessibility
Semaglutide, marketed under the brand names Wegovy for weight management and Ozempic for diabetes, was classified as an essential medicine by the World Health Organization (WHO) in September 2022. However, the exorbitant prices have remained a considerable obstacle to access. The new analysis suggests that with the expiration of patents in various countries, mass production of the injectable form of semaglutide could drive costs down to levels that would make it affordable for millions.
The research indicates that while the injectable formulation can be produced for about $3 (approximately £2.35) per month, oral versions might be available for around $16 monthly. Dr Andrew Hill from Liverpool University’s pharmacology department remarked, “These low prices open the door to worldwide access to an essential medicine,” highlighting the transformative potential of this development.
Patent Expirations and Global Health Impact
The study identifies that core patents for semaglutide are set to expire in ten countries this year, including Brazil, China, India, South Africa, Turkey, Mexico, and Canada, paving the way for generic competition. Moreover, researchers noted that another 150 countries, many in Africa, have not filed patents, indicating that 69% of the global population living with type 2 diabetes and 84% of those with obesity reside in these regions.
Prof François Venter from Witwatersrand University in Johannesburg pointed out that similar pricing strategies for drugs treating other conditions, such as HIV and tuberculosis, have saved millions of lives. He asserted, “We can repeat this medical success story for semaglutide,” underscoring the potential benefits of making these critical medications more accessible.
Challenges Beyond Cost
Despite the promising outlook regarding affordability, experts caution that merely lowering prices will not tackle the underlying causes of obesity, which include food insecurity, poverty, urbanisation, and the prevalence of unhealthy food environments. Dr Nomathemba Chandiwana, chief scientific officer at South Africa’s Desmond Tutu Health Foundation, emphasised the need for coordinated policies and comprehensive procurement planning to ensure that the benefits of affordable semaglutide are realised effectively across health systems.
Chandiwana further noted that approximately 27% of adults globally meet the criteria for medications such as semaglutide, with the majority living in low- and middle-income countries where access remains critically limited. The pressing challenge is how to responsibly integrate these treatments into holistic strategies for obesity and diabetes care.
The Growing Diabetes Epidemic
The global diabetes epidemic has seen alarming growth, with the number of affected individuals soaring from 200 million in 1990 to an estimated 830 million in 2022. This increase has been particularly pronounced in low and middle-income nations, where lifestyle changes and dietary shifts towards ultra-processed foods have exacerbated health outcomes. Obesity is linked to a myriad of serious health conditions, including heart disease, stroke, and various cancers, contributing to approximately 3.7 million deaths annually.
Although semaglutide received regulatory approval in the United States in 2017, it is currently priced around $200 per month in the US and approximately £120 in the UK, with patent protections in these regions not due to expire for another five years. These high costs have limited access to a significant portion of the population that could benefit from this essential medication.
Why it Matters
The findings from this recent analysis represent a critical turning point in the fight against global diabetes and obesity. By making semaglutide affordable, millions of individuals in resource-limited settings could gain access to vital treatments that have the potential to dramatically improve health outcomes. However, the success of this initiative relies not only on reducing costs but also on addressing systemic issues that contribute to obesity and diabetes. As nations grapple with escalating healthcare demands, the need for comprehensive strategies that encompass medication access and broader societal changes has never been more urgent.
